FME.F - Fresenius Medical Care AG & Co. KGaA

Frankfurt - Frankfurt Delayed Price. Currency in EUR
60.42
+0.52 (+0.87%)
At close: 6:48PM CEST
Stock chart is not supported by your current browser
Previous Close59.90
Open60.06
Bid60.26 x 100000
Ask60.48 x 100000
Day's Range60.00 - 60.42
52 Week Range55.00 - 91.42
Volume245
Avg. Volume866
Market Cap17.973B
Beta (3Y Monthly)1.26
PE Ratio (TTM)14.99
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.17 (1.95%)
Ex-Dividend Date2019-05-17
1y Target EstN/A
  • Zacks Small Cap Research

    CTSO: Q2 19: Product Sales Rebound to Record High Despite Distributor Hangover. Value-Inflection Opportunities Abound

    ‣ Record Revenue, Margins: Q2 set records on Product Revenue, Total Revenue, Direct Sales and Product Margin. CytoSorbents (CTSO) expects all three to be back online by year-end (one of which resumed ordering in Q2).

  • Cytosorbents (CTSO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Cytosorbents (CTSO) Q2 2019 Earnings Call Transcript

    CTSO earnings call for the period ending June 30, 2019.

  • Fresenius Medical Care AG & Co. KGaA (FMS) Q2 2019 Earnings Call Transcript
    Motley Fool

    Fresenius Medical Care AG & Co. KGaA (FMS) Q2 2019 Earnings Call Transcript

    FMS earnings call for the period ending July 30, 2019.

  • CVS Health Tests Home Dialysis System; DaVita, Fresenius Hit
    Investor's Business Daily

    CVS Health Tests Home Dialysis System; DaVita, Fresenius Hit

    CVS Health began a trial of a home dialysis system that could cut into a market controlled by Fresenius Medical and DaVita. But all three stocks fell.

  • Morningstar

    Home Dialysis to Benefit These Undervalued Providers

    Specifically, the U.S. Department of Health and Human Services has proposed potential changes to reimbursement policy that are likely to encourage home treatment for kidney failure. While the stocks of both companies look cheap following recent underperformance, we think DaVita's nearly 30% discount to our fair value estimate presents a compelling investment opportunity. The two primary modalities amenable to at-home treatment are hemodialysis and peritoneal dialysis.

  • Reuters

    UPDATE 3-Trump administration pushes U.S. at-home kidney care, transplant availability

    NEW YORK/WASHINGTON, July 10 (Reuters) - The Trump administration on Wednesday set goals to move more kidney disease treatment into patients' homes and increase transplants while reducing the U.S. reliance on more costly dialysis clinics. President Donald Trump signed an executive order underscoring these goals, and the U.S. health agency said it would test new payment structures, including one that rewards end-stage renal disease facilities and doctors who meet targets in these areas. The U.S. government spends $114 billion each year to treat chronic kidney disease and end-stage renal disease.

  • TheStreet.com

    DaVita Lower as HHS Plans to Emphasize At-Home Dialysis Treatment

    A looming federal health-care shift has the potential to shake up the $24 billion dialysis industry, in which DaVita is a leading player.

  • Reuters

    Fresenius makes solid start to year after turbulent 2018

    Fresenius reported a rise in first-quarter sales and operating profit on Thursday, helped by growth at its generic infusion drugs and dialysis units, as its troubled German hospital business showed signs of stabilisation. Currency-adjusted quarterly sales rose 5 percent to 8.5 billion euros (£7.3 billion), helped by growth at its Kabi infusion unit and separately listed Fresenius Medical Care. "All four Fresenius business segments have developed in line with our expectations, putting us well on course to meet our targets for the year," Chief Executive Stephan Sturm said.

  • Reuters

    Fresenius Medical Care to pay $231 mln to resolve criminal, civil foreign bribery charges

    Germany-based dialysis clinic operator Fresenius Medical Care AG will pay about $231 million to resolve criminal and civil allegations that the company paid bribes to public health and government officials in several countries to win or retain business, the U.S. Justice Department said on Friday. The Justice Department agreed not to prosecute the company criminally in exchange for Fresenius paying a penalty of $84,715,273. The Securities and Exchange Commission, meanwhile, ordered the company to pay $147 million in disgorgement and prejudgment interest to settle the civil charges.

  • Reuters

    Fresenius Medical Care says U.S. settlement will not affect 2019, 2020 results

    Fresenius Medical Care AG said that a $231.7 million U.S. settlement reached on Friday to resolve bribery allegations would have no impact on its 2019 and 2020 results because it had already made a financial ...

  • Reuters

    U.S. seeks to cut dialysis costs with more home care versus clinics

    The goal is to reduce the $114 billion paid by the U.S. government each year to treat chronic kidney disease and end-stage renal disease, a top area of spending. The U.S. Centers for Medicare and Medicaid Services (CMS), which provides Medicare health benefits to more than 55 million Americans, is looking at a trial payment design that would improve care in the early stages of kidney disease, increase access to kidney transplants and favor home dialysis over clinic-based treatment, CMS head Seema Verma told Reuters in an interview.

  • Reuters

    FMC wraps up $2 bln acquisition of NxStage

    Germany's Fresenius Medical Care (FMC) wrapped up its $2 billion acquisition of U.S. home dialysis maker NxStage Medical on Friday, according to a U.S. Securities and Exchange Commission filing. The closure - some 18 months after FMC agreed to buy NxStage - paves the way for the world's biggest provider of dialysis services to scale up its home dialysis business by investing in new infrastructure, patient training and education.

  • Fresenius Medical Care AG & Co. (FMS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool

    Fresenius Medical Care AG & Co. (FMS) Q4 2018 Earnings Conference Call Transcript

    FMS earnings call for the period ending December 31, 2018.

  • FMC expects NxStage deal to close in next couple of days
    Reuters

    FMC expects NxStage deal to close in next couple of days

    Germany's Fresenius Medical Care (FMC) said on Wednesday it has won the green light from U.S. regulators to acquire U.S. home dialysis equipment maker NxStage and expects the deal to close in the next few days. FMC agreed to buy NxStage in August 2017 for $2 billion but the deal has been held up due to competition concerns and most recently the U.S. government shutdown. "Very early this morning, we were notified the Federal Trade Commission has approved our NxStage deal," Chief Executive Rice Powell told reporters.

  • Reuters

    Fresenius flags faster earnings growth from 2020 after investment

    Fresenius expects earnings to grow faster than sales from 2020 after investments to improve its German hospitals and scale up its home dialysis business eat up profit this year, the German healthcare group said on Wednesday. Investors, who were disappointed last year after the company trimmed its guidance in October and abandoned in 2020 targets in December, were heartened by the outlook and the prospect of a 7 percent increase in the dividend to 0.80 euros per share. "2019 will be a year of investment in growth areas such as home dialysis, biosimilars and new hospital services and therapies," Chief Executive Stefan Sturm said in a statement.

  • Reuters

    Fresenius Medical Care plans 1 bln eur share buyback

    Fresenius Medical Care, the world's biggest provider of dialysis services, signalled a return to profit growth from 2020 on Wednesday and said it would buy back shares worth 1 billion euros ($1.13 billion) over the next two years. FMC, which has been burdened by a lower percentage of its patients on higher paying insurance schemes and contributions to campaigns to lobby against state ballot initiatives, said it expects adjusted sales growth of between 3-7 percent in 2019.